Cardiovascular Disease: The Other Face of Diabetes


Despite glycemic control, evidence suggests that mortality and morbidity remain high in diabetes. Regulatory agencies deem, therefore, additional safety trials necessary for the approval of new antidiabetic drugs. Nevertheless, markers of cardiovascular risk, which can be used as response predictors, are not available. In contrast with current efforts on… (More)
DOI: 10.1038/psp.2013.57


Cite this paper

@inproceedings{Vlasakakis2013CardiovascularDT, title={Cardiovascular Disease: The Other Face of Diabetes}, author={Georgios Vlasakakis and Oscar Della Pasqua}, booktitle={CPT: pharmacometrics & systems pharmacology}, year={2013} }